Views & Analysis Verily, Novartis join fund to support Europe’s biotech entre... New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition
News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
News Bicycle Therapeutics picks up speed with £40m fundraising First-in-class compound set to enter phase 1 trials later this year
News Takeda signs deal with UK biotech GammaDelta Therapeutics on... UK biotech pioneering new type of T cell immunotherapy
News Serial entrepreneur Huntingdon raises funds for latest biote... Z Factor, a University of Cambridge spin-out company has raised £7 million in a Series A investment
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.